Risk factor analysis for survival at relapse among 75 patients with relapsed BL/B-AL diagnosed between 2001 and 2016: univariate analysis
| Characteristics . | Patients, n . | Event, n . | Survival at 4 y, % . | P . |
|---|---|---|---|---|
| Initial CNS involvement | ||||
| Positive | 20 | 18 | 10 ± 7 | .13 |
| Negative | 55 | 37 | 33 ± 6 | |
| Progression/relapse during initial therapy | ||||
| Yes | 28 | 25 | 11 ± 7 | .001 |
| No | 47 | 30 | 36 ± 7 | |
| Initial therapy branch | ||||
| R1/R2 | 14 | 7 | 50 ± 13 | .017 |
| R3/R4 | 61 | 48 | 21 ± 5 | |
| Rituximab during initial therapy (n = 70) | ||||
| No | 60 | 42 | 30 ± 6 | .04 |
| Yes | 10 | 9 | 10 ± 9 | |
| CNS involvement at relapse | ||||
| Positive | 22 | 18 | 18 ± 8 | .56 |
| Negative | 53 | 37 | 30 ± 6 | |
| BM at relapse | ||||
| Positive | 26 | 18 | 31 ± 9 | .91 |
| Negative | 48 | 36 | 25 ± 6 | |
| Rituximab in relapse (n = 63) | ||||
| No | 13 | 13 | .016 | |
| Yes | 55 | 35 | 36 ± 6 | |
| Progression during re-induction (n = 68) | ||||
| No | 36 | 17 | 53 ± 8 | <.001 |
| Yes | 32 | 31 | 3 ± 3 | |
| CR before SCT (SCT n = 46) | ||||
| Yes | 30 | 11 | 63 ± 9 | <.001 |
| No | 16 | 15 | 6 ± 6 | |
| Reinduction regimen (n = 71) | ||||
| VICI | 15 | 5 | 67 ± 12 | .003 |
| All other | 56 | 46 | 18 ± 5 |
| Characteristics . | Patients, n . | Event, n . | Survival at 4 y, % . | P . |
|---|---|---|---|---|
| Initial CNS involvement | ||||
| Positive | 20 | 18 | 10 ± 7 | .13 |
| Negative | 55 | 37 | 33 ± 6 | |
| Progression/relapse during initial therapy | ||||
| Yes | 28 | 25 | 11 ± 7 | .001 |
| No | 47 | 30 | 36 ± 7 | |
| Initial therapy branch | ||||
| R1/R2 | 14 | 7 | 50 ± 13 | .017 |
| R3/R4 | 61 | 48 | 21 ± 5 | |
| Rituximab during initial therapy (n = 70) | ||||
| No | 60 | 42 | 30 ± 6 | .04 |
| Yes | 10 | 9 | 10 ± 9 | |
| CNS involvement at relapse | ||||
| Positive | 22 | 18 | 18 ± 8 | .56 |
| Negative | 53 | 37 | 30 ± 6 | |
| BM at relapse | ||||
| Positive | 26 | 18 | 31 ± 9 | .91 |
| Negative | 48 | 36 | 25 ± 6 | |
| Rituximab in relapse (n = 63) | ||||
| No | 13 | 13 | .016 | |
| Yes | 55 | 35 | 36 ± 6 | |
| Progression during re-induction (n = 68) | ||||
| No | 36 | 17 | 53 ± 8 | <.001 |
| Yes | 32 | 31 | 3 ± 3 | |
| CR before SCT (SCT n = 46) | ||||
| Yes | 30 | 11 | 63 ± 9 | <.001 |
| No | 16 | 15 | 6 ± 6 | |
| Reinduction regimen (n = 71) | ||||
| VICI | 15 | 5 | 67 ± 12 | .003 |
| All other | 56 | 46 | 18 ± 5 |